Key insights
- Outset Medical (OM) announced a $40 million contract with HCA for new Tablo Hemodialysis Systems, potentially driving the company towards profitability and positive cash flow. This deal, significantly above its current market cap, highlights the disruptive potential of OM's technology in addressing high-cost, undercompensated dialysis treatments. With strong gross margins and substantial cash reserves, the agreement is expected to attract growth and special situations investors, signaling a positive near-term outlook for the company's stock.
This is a meaningful announcement delivered via an 8-K filing with the SEC. OM was expected to generate $127 million in revenue this year so this sale of $40 million which has further upside stands out. This should push the company into profitability and cash flow positive position so it reduces risk very much. Even with the stock up today it is only an $87 million market cap. Well below 1X sales. And their systems which offer a far better way of delivering dialysis have a ton of upside. Many patients “crash” into the ER with kidney failure, and must be maintained in the critical care unit for which the hospital does Not receive adequate compensation for this people intensive (high cost) treatment. OM’s systems solve this. That’s why HCA is contracting with them. Gross margins are near 50% and as they scale opex the drop down will be high. OM has $157mm in cash on their balance sheet. Growth and special situations investors will take notice of this name.
Outset Medical Files 8K - Entry Into Definitive Agreement >OM 2026-06-17 20:06:10 GMT
(Dow Jones) -- Outset Medical Inc. (OM) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on June 17, 2026.
On June 14, 2026, Outset Medical, Inc., (the "Company") entered into the Refresh Amendment (the "Amendment") to the Purchasing Agreement with HCA Management Services, L.P. ("HCA"), dated May 1, 2020, as amended (collectively, the "Agreement").
Under the terms of the Amendment, the parties have agreed, among other things, for HCA to refresh its existing fleet of Tablo Hemodialysis Systems by purchasing new Tablo Hemodialysis Systems commencing in 2026 through the end of 2028, for an aggregate contract value, net of rebates and allowances, of approximately $40 million. This committed capital purchase agreement also provides a console and consumables purchase framework that supports potential future growth beyond the HCA hospitals that have already adopted the hemodialysis in-sourcing model with Tablo.